Nikulaa Parachuri

ASTER — Canada

Medicine · Health Sciences

14h-index726citations70works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Retinal Diseases and Treatments(37), Retinal and Optic Conditions(24), Biosimilars and Bioanalytical Methods(20), Retinal Imaging and Analysis(17), Systemic Lupus Erythematosus Research(10)

Publications70 total

Aflibercept vs ranibizumab biosimilars: manufacturing differences that might matter in the long run
Eye·2025Open Access
FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings – FORCE study
Eye·2025· 2 cited
The conundrum of abundance: challenges of having too many biosimilars
Expert Opinion on Biological Therapy·2025· 2 cited
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study
Journal of VitreoRetinal Diseases·2025· 5 citedOpen Access
Aflibercept 2 mg biosimilars—will they lead the Anti-VEGF biosimilar world globally
Eye·2025· 5 cited
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI)
Eye·2024· 11 citedOpen Access
Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study
Eye·2024Open Access
Global experience of faricimab in clinical settings - a review
Expert Opinion on Biological Therapy·2024· 11 cited
Electroretinogram as a Screening Tool to Assess Vigabatrin-Induced Retinal Toxicity in Children With Infantile Spasms
Journal of Pediatric Ophthalmology & Strabismus·2024· 2 cited
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs
Eye·2024· 2 citedOpen Access
Aflibercept biosimilars – update on the development progress
Eye·2023· 4 citedOpen Access
Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases
Journal of VitreoRetinal Diseases·2023· 7 citedOpen Access
Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?
Eye·2023· 5 citedOpen Access
Re: Zhang et al.: The biosimilar paradox: how anti-VEGF biosimilars will increase patient and overall healthcare costs (Ophthalmology. 2023;130:966-973)
Ophthalmology·2023· 1 citedOpen Access
Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia
Expert Opinion on Biological Therapy·2023· 3 cited
Acute zonal occult outer retinopathy – An acquired bilaterally symmetrical fovea-sparing lesion
Indian Journal of Ophthalmology - Case Reports·2023Open Access
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)
Expert Opinion on Biological Therapy·2023· 22 citedOpen Access
Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists
International Journal of Retina and Vitreous·2023· 28 citedOpen Access
Post-COVID ischemic maculopathy – A case report
Journal of Clinical Ophthalmology and Research·2023Open Access
Multimodal imaging analysis and treatment outcome after 1-year follow-up of probable unilateral Vogt–Koyanagi–Harada disease: A case report
EyeQuest·2023Open Access
page 1 of 4Next →

Frequent Co-authors

Ashish Sharma(48), Nilesh Kumar(48), Baruch D. Kuppermann(43), Francesco Bandello(41), Anat Loewenstein(18), Carl D. Regillo(14), Anat Loewenstein(11), David S. Boyer(6), Rohini Sharma(6), Usha Chakravarthy(5), Giulia Corradetti(4), Peter K. Kaiser(4), Quan Dong Nguyen(4), Se Joon Woo(4), Srinivas R. Sadda(3), Arshad M. Khanani(3), Frank G. Holz(3), David Sarraf(3), Şengül Özdek(3), Paolo Lanzetta(3)